RE: Casanova Lab Tweet9 Jun 2021 15:36
I can access the paper but due to copyright can't repost all of it here - however here is the conclusion:
Insight that type I IFN defects underlie severe COVID-19 in at least 10% of patients challenges past, ongoing, and future trials and clinical treatment strategies. Here, we discussed how findings from the COVIDhge provide a rationale for targeted interventions during specific phases of COVID-19 pathogenesis. Early testing can identify individuals with defects in the type I IFN circuit, whether genetically or serologically mediated, who stand to most benefit from IFN-ß therapy prior to or during the early viral replication phase. In addition, the efficacy of IFN-ß therapy would not be anticipated to be affected by the infecting SARS-CoV-2 variant. Those hospitalized and found to harbor neutralizing auto-Abs to type I IFN might benefit from TPE. Ideally, trials should be designed to specifically address these different treatment groups. Our findings also raise important questions about some of the current approaches being evaluated, e.g., the use of convalescent plasma and the use of Jakinibs. Finally, despite the advent of efficacious vaccines in the general population, patients with defects of type I IFN immunity may continue to remain at risk, for example, due to impaired innate responses in the face of emerging variants or to sub-optimal adaptive immunity. The ongoing work of our consortium, in conjunction with the recent promising results of IFN-ß in treatment of SARS-CoV-2 infection, opens bold new avenues in the global fight against this pandemic.
Sign In
Follow the stocks
